Jason P. Rhodes SEC Filing Summary

On April 23-27, 2026, Jason P. Rhodes, a director at Dyne Therapeutics, Inc. (DYN), reported the sale of a significant number of common shares. These transactions were executed under a Rule 10b5-1 trading plan. The sales occurred over three days with varying prices. On April 23rd, shares were sold at a weighted average price of $19.19, with individual transactions ranging from $19.00 to $19.45. On April 24th, the weighted average selling price was $18.48, with prices ranging from $18.1272 to $19.035. On April 27th, the weighted average price was $18.15, with transactions ranging from $18.00 to $18.445. The shares sold were held indirectly through various investment funds, including Atlas Venture Opportunity Fund II, L.P., Atlas Venture Fund XI, L.P., and Atlas Venture Opportunity Fund I, L.P. Rhodes, while a member of the general partners of these funds, disclaims beneficial ownership except to the extent of any pecuniary interest.